Delivery Order SPE2DB20D1100-SPE2DB25FE1AY
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Ozempic 2 mg/dose (8 mg/3 mL) in 3 mL vials, with a ceiling value of $12,533.20. This non-set-aside, firm fixed price delivery order is scheduled for completion by September 11, 2025, and will be performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. The award represents a continuation of AmerisourceBergen's extensive pharmaceutical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 mL) in 3 mL vials, with a contract ceiling value of $10,135.84. This is a firm fixed-price delivery order with no set-aside designation, reflecting a competitively awarded procurement. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 5, 2025. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 26, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 mL) in 3 mL vials, with a ceiling value of $3,759.96. This competitively awarded, firm fixed-price delivery order is scheduled for completion by August 27, 2025, with performance at AmerisourceBergen's Conshohocken, Pennsylvania facility. The contract represents a small-value transaction typical of the company's regular medical supply deliveries...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 26, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 mL) in 3 mL vials, with a ceiling value of $8,146.58 and an ultimate completion date of September 29, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and represents a continuation of AmerisourceBergen's pharmaceutical supply services under the Defense Logistics Agency's Medical Supply Chain...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 mL) in 3 mL vials, with a ceiling value of $42,011.63. This firm fixed-price delivery order, which is set to be completed by August 5, 2025, will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a routine pharmaceutical procurement within the Defense Logistics Agency's medical supply...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 mL) in 3 mL vials, with a ceiling value of $37,730.25. This competitively awarded, firm fixed-price delivery order is set to be completed by August 20, 2025, and will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The contract represents a routine pharmaceutical procurement supporting federal medical supply...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 18, 2025, for the supply of Ozempic 2 mg/dose (8 mg/3 mL) in 3 mL vials, with a ceiling value of $4,552.06. This is a firm fixed-price delivery order with an ultimate completion date of September 19, 2025, and represents a competitively awarded, non-set-aside contract. The order will be fulfilled from AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 mL) 3 mL vials with a ceiling value of $29,042.05. This firm fixed-price delivery order, which is set to be completed by August 19, 2025, will be fulfilled from the vendor's location in Conshohocken, Pennsylvania. The award represents a competitive procurement with no set-aside designation, reflecting AmerisourceBergen's demonstrated capability to...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 26, 2025, for the supply of Ozempic 2 mg/dose (8 mg/3 ml) in 3 ml vials, with a contract ceiling value of $49,655.94. This is a firm fixed-price delivery order issued under a competitive procurement with no set-aside designation. The award reflects AmerisourceBergen's role as a critical pharmaceutical distributor supporting federal medical supply chains, with performance to take place at the company's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 mL) 3 mL vials with a ceiling value of $42,114.61. This competitively awarded, firm fixed-price delivery order is non-set-aside and carries an ultimate completion date of August 4, 2025, with performance at AmerisourceBergen's Conshohocken, Pennsylvania facility. The award represents a continuation of AmerisourceBergen's role as a critical...
- SPE2DB20D1100Indefinite Delivery Contract
- SPE2DB20D1100-SPE2DB25FE1AYDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 24, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 ml) 3 ml vials with a ceiling value of $9,142.84 under firm fixed pricing. This is a non-set-aside competitive award structured as a delivery order with an ultimate completion date of September 25, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. This prime contract vehicle provides comprehensive pharmaceutical and medical supply support to military healthcare systems globally, including the Defense Health Agency and U.S. Coast Guard. AmerisourceBergen, a major pharmaceutical distributor and critical federal medical procurement vendor, regularly fulfills delivery orders for brand-name and generic medications across multiple therapeutic domains through this expansive DLA contract framework.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $9.1k | 9/24/25 |